‘Sprinkle’ Method of Giving Kadian Capsules Approved

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

WILMINGTON, Del-The FDA has cleared an alternative method of administration of the pellets contained in Zeneca’s Kadian (morphine sulfate sustained release) capsules.

WILMINGTON, Del—The FDA has cleared an alternative method of administration of the pellets contained in Zeneca’s Kadian (morphine sulfate sustained release) capsules.

Rather than being swallowed whole, now the capsules may be opened and the entire contents sprinkled on a small amount of applesauce immediately prior to ingestion. The pellets should not be chewed, crushed, or dissolved due to risk of overdose, the company said.

In a study of healthy volunteers, Kadian pellets sprinkled over applesauce were found to be bioequivalent to Kadian capsules swallowed whole with apple-sauce under fasting conditions. With the sprinkle administration, patients should consume the entire portion and should not divide the applesauce into separate doses. Other foods for use with Kadian pellets have not been tested in patients.

Kadian is prescribed for the management of moderate-to-severe chronic pain when treatment with an opioid analgesic is indicated for more than a few days.

“The recent approval of Kadian in sprinkle-supplement form allows patients who experience moderate-to-severe pain, and have difficulty swallowing capsules or tablets, 24-hour pain control with the option of a single dose,” said oncologist Robert Kerr, MD, of Southwest Regional Cancer Center, Austin, Tex.

Recent Videos
7 experts are featured in this series.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content